VEA
SIOX

Virtus ETF Advisers’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Virtus ETF Advisers’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-15,557
Closed -$301K – 403
2018
Q3 		$301K Sell
15,557
-11,306
-42% -$206K 0.03% 188
2018
Q2 		$486K Buy
26,863
+9,567
+55% +$141K 0.43% 136
2018
Q1 		$184K Buy
17,296
+9,010
+109% +$145K 0.16% 117
2017
Q4 		$349K Buy
8,286
+6,517
+368% +$292K 0.44% 90
2017
Q3 		$97K Buy
1,769
+162
+10% +$27.3K 0.01% 143
2017
Q2 		$298K Sell
1,607
-1,181
-42% -$207K 0.04% 125
2017
Q1 		$333K Buy
2,788
+268
+11% +$28.1K 0.06% 127
2016
Q4 		$250K Buy
2,520
+137
+6% +$14.4K 0.07% 143
2016
Q3 		$267K Hold
2,383
– – 0.13% 118
2016
Q2 		$245K Buy
2,383
+811
+52% +$81.1K 0.18% 94
2016
Q1 		$144K Buy
+1,572
New +$168K 0.2% 125

Other funds holding SIOX

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Virtus ETF Advisers's SIOX Position: Q4 2018 in Review

Virtus ETF Advisers sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2018, closing a stake of 15,557 shares — an estimated $301K sold.

Virtus ETF Advisers first reported a position in SIOX in Q1 2016 and held it in 11 quarters. The position peaked at $486K in Q2 2018. 61 funds tracked by Wall St. Rank hold SIOX as of Q4 2018.

  • Virtus ETF Advisers reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Virtus ETF Advisers sold 15,557 Sio Gene Therapies Inc. Common Stock shares in Q4 2018, an estimated $301K.
  • Virtus ETF Advisers first reported a position in Sio Gene Therapies Inc. Common Stock in Q1 2016 and held it in 11 quarters.
  • Virtus ETF Advisers's Sio Gene Therapies Inc. Common Stock position peaked at $486K in Q2 2018.
  • 61 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2018.

Based on Virtus ETF Advisers's 13F filing for Q4 2018, filed 5 Feb 2019.